1. Shammas NW. An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors. Int J Angiol. 2013; 22:1–8.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012; 59:16–23.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Ko YG, Ahn CM, Min PK, et al. Baseline characteristics of a retrospective patient cohort in the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) Registry. Korean Circ J. 2017; 47:469–476.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996; 94:1247–1254.
5. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100:1872–1878.
6. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005; 45:312–315.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011; 4:495–504.
8. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010; 3:267–276.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Shishehbor MH. Endovascular treatment of femoropopliteal lesions: so many options, little consensus. J Am Coll Cardiol. 2015; 66:2339–2342.
10. Byrne RA, Joner M, Alfonso F, et al. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014; 11:13–23.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Cassese S, Byrne RA, Ott I, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012; 5:582–589.
12. Krankenberg H, Tübler T, Ingwersen M, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized Femoral Artery In-stent Restenosis (FAIR) trial. Circulation. 2015; 132:2230–2236.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Kinstner CM, Lammer J, Willfort-Ehringer A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. JACC Cardiovasc Interv. 2016; 9:1386–1392.
14. Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012; 60:1739–1742.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Virga V, Stabile E, Biamino G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014; 7:411–415.
16. Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014; 21:1–8.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Grotti S, Liistro F, Angioli P, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study. J Endovasc Ther. 2016; 23:52–57.
18. Brodmann M, Keirse K, Scheinert D, et al. Drug-coated balloon treatment for femoropopliteal artery disease: the IN.PACT global study de novo in-stent restenosis imaging cohort. JACC Cardiovasc Interv. 2017; 10:2113–2123.
19. Bosiers M, Deloose K, Keirs K, et al. Prevention and treatment of in-stent restenosis. J Cardiovasc Surg (Torino). 2010; 51:591–598.
20. Gorgani F, Telis A, Narakathu N, et al. Long-term outcomes of the Viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery. J Invasive Cardiol. 2013; 25:670–674.
21. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013; 6:274–281.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Tomoi Y, Soga Y, Iida O, et al. Impact of drug-eluting stent implantation for femoropopliteal in-stent occlusion. J Endovasc Ther. 2016; 23:461–467.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Murata N, Takahara M, Soga Y, et al. Drug-eluting stent vs percutaneous transluminal angioplasty for treatment of femoropopliteal in-stent restenosis: results from a retrospective 1-year multicenter study. J Endovasc Ther. 2016; 23:642–647.
24. Katsanos K, Spiliopoulos S, Reppas L, et al. Debulking atherectomy in the peripheral arteries: is there a role and what is the evidence? Cardiovasc Intervent Radiol. 2017; 40:964–977.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015; 8:92–101.
26. Laird JR Jr, Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv. 2012; 80:852–859.
27. Shammas NW, Shammas GA, Banerjee S, et al. JetStream rotational and aspiration atherectomy in treating in-stent restenosis of the femoropopliteal arteries: results of the JETSTREAM-ISR feasibility study. J Endovasc Ther. 2016; 23:339–346.
28. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013; 58:682–686.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Gandini R, Del Giudice C, Merolla S, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013; 20:805–814.
![crossref](/image/icon/bnr_ref_cross.gif)